Posted by Michael Wonder on 14 Apr 2021
TGA grants provisional determination to GSK for COVID-19 monoclonal antibody treatment - sotrovimab
14 April 2021 - The TGA has granted a provisional determination to GSK in relation to the monoclonal antibody treatment, sotrovimab (GSK4182136).
The granting of a provisional determination means that the TGA has made a decision that GSK is now eligible to apply for provisional registration for the treatment in the Australian Register of Therapeutic Goods.
